Global Pharmaceuticals Outlook, 2022

Global Pharmaceuticals Outlook, 2022

Frost & Sullivan offers an outlook for the global pharmaceuticals market for 2022-2026, including emerging trends and growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting the global mitigation of the COVID-19 pandemic, which is resulting in severe implications on health and social and economic well-being and delaying endemicity. The ongoing pandemic has accelerated pharma and biotech companies' transformation, and clinical trial decentralization, data-driven R&D, the digitalization of the supply chain, and outsourcing have taken center stage.

The industry will focus on supply chain resilience and the adoption of innovative technologies to improve efficiency while ensuring that healthcare remains precise, preventive, and outcome-based in the promotion of social and financial inclusion. In 2021, the emphasis was on COVID-19 in terms of drug research and therapy administration; this trend is expected to change by the end of 2022, and oncology and CNS are expected to become leading growth areas for the pharma industry. Value-based care will take center stage and lead to a shift to platform- and data-based drug discovery and development models.

KEY ISSUES ADDRESSED

What is the size of the global pharmaceuticals industry from 2022 to 2026?
What are the dynamics around COVID-19 vaccination deployment and the path to endemicity?
How are advancements such as decentralization, blockchain, and new modalities driving the transformation of the pharmaceuticals value chain?
What is the current and future therapeutic, R&D, and investment outlook and how is it evolving?
Which growth opportunities can ecosystem participants leverage in the near future?